ProMIS Neurosciences Q2 2023 Earnings Report $0.82 -0.09 (-9.45%) As of 02/21/2025 03:58 PM Eastern Earnings History ProMIS Neurosciences EPS ResultsActual EPS-$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AProMIS Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AProMIS Neurosciences Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call ResourcesPMN Earnings History ProMIS Neurosciences Earnings HeadlinesProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating OfficerFebruary 20 at 11:30 AM | marketwatch.comProMIS Neurosciences seperates from COO Malenfant, terminates COO positionFebruary 20 at 11:30 AM | markets.businessinsider.comMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.February 22, 2025 | Colonial Metals (Ad)ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comSee More ProMIS Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProMIS Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProMIS Neurosciences and other key companies, straight to your email. Email Address About ProMIS NeurosciencesProMIS Neurosciences (NASDAQ:PMN) discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.View ProMIS Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
